ACR Convergence 2022

November 10-14, 2022. Philadelphia, PA.

View by Number View by Title View Sessions

View by Date

Saturday, November 12, 2022

1:00PM-3:00PM: Abstract Number: 0491

Markers of Neutrophil Activation in Patients with ANCA-associated Vasculitis and Large-vessel Vasculitis

Vasculitis – Non-ANCA-Associated and Related Disorders Poster I: Giant Cell Arteritis

1:00PM-3:00PM: Abstract Number: 0054

MDSCs in Inflammatory Joints of SKG Mice Suppress T Cells and Differentiate into Osteoclasts

RA – Animal Models Poster

1:00PM-3:00PM: Abstract Number: 0320

Metabolomics in Systemic Lupus Erythematosus and Pregnancy – A Prospective Observational Longitudinal Study

SLE – Diagnosis, Manifestations, and Outcomes Poster I: Diagnosis

1:00PM-3:00PM: Abstract Number: 0028

Microenvironmental Stiffness Modulates Macrophage Responsiveness and Communication with Mesenchymal Stem Cells

Osteoarthritis and Joint Biology – Basic Science Poster

1:00PM-3:00PM: Abstract Number: 0170

Minimal Clinically Important Difference in Myositis Response Criteria

Muscle Biology, Myositis and Myopathies Poster I

1:00PM-3:00PM: Abstract Number: 0252

Mitochondrial Content in Skeletal Muscle of Individuals with Rheumatoid Arthritis Is Associated with Physical Activity Level

RA – Diagnosis, Manifestations, and Outcomes Poster I

1:00PM-3:00PM: Abstract Number: 0041

Modeling Juvenile Dermatomyositis with Engineered Human Skeletal Muscle: Effects of Type I Interferonβ and Janus Kinase Inhibitors

Pediatric Rheumatology – Basic Science Poster

1:00PM-3:00PM: Abstract Number: 0233

Monoarthritis Virtual Teaching Module for Rheumatology Learners

Professional Education Poster

1:00PM-3:00PM: Abstract Number: 0248

Monocyte Chemoattractant Protein-1, Vascular Cell Adhesion Protein-1 and Asymmetric Dimethylarginine as Potential Biomarkers of Interstitial Lung Disease Associated with RA

RA – Diagnosis, Manifestations, and Outcomes Poster I

1:00PM-3:00PM: Abstract Number: 0381

Most Disease Outcome Measures but Not ASDAS Are Influenced by Gender in Patients with Axial SpA: Results from ASAS-PerSpA

Spondyloarthritis Including PsA – Diagnosis, Manifestations, and Outcomes Poster I

1:00PM-3:00PM: Abstract Number: 0493

MRI Is Superior to Ultrasound of Supraaortic Arteries in Detecting Giant Cell Arteritis – Experience of a Single Center

Vasculitis – Non-ANCA-Associated and Related Disorders Poster I: Giant Cell Arteritis

1:00PM-3:00PM: Abstract Number: 0342

Multi-Parametric Interrogation of the Systemic Lupus Erythematosus (SLE) Immunome Reveals Multiple Derangements

SLE – Diagnosis, Manifestations, and Outcomes Poster I: Diagnosis

1:00PM-3:00PM: Abstract Number: 0335

Multiplexed Mass Cytometry of Cutaneous Lupus Erythematosus and Dermatomyositis Skin: An In-depth B Cell Directed Immunoprofile

SLE – Diagnosis, Manifestations, and Outcomes Poster I: Diagnosis

1:00PM-3:00PM: Abstract Number: 0178

Muscle Fibres Play a Critical Role in Therapeutic Response of Myositis to Glucocorticoids Through Polarisation of the Inflammatory Infiltrate by a Paracrine Mechanism

Muscle Biology, Myositis and Myopathies Poster I

1:00PM-3:00PM: Abstract Number: 0143

National Multicenter Study of 80 Patients with Refractory Uveitis Due to Immune-Mediated Inflammatory Diseases Treated with Certolizumab Pegol

Miscellaneous Rheumatic and Inflammatory Diseases Poster I

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].